What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The Placebo equivalent of CBT-248 will be administered as oral vegetable (cellulose) capsules that visually match the active treatment.”In the company’s words, NCT07905053 on ClinicalTrials.gov
- Tested for
- Chronic Pancreatitis
- Main trialPhase 1
- “This study will test CBT-248, an experimental medicine being developed for chronic pancreatitis. Chronic pancreatitis causes ongoing inflammation and damage to the pancreas, which can cause pain and problems with digestion and blood sugar control. The study will involve 32 healthy adults. It will look at side effects at different doses, measure the amount of medicine in the blood over time, and examine whether taking it with food changes these amounts. Participants will be divided into four groups of eight. In each group, six people will receive CBT-248 and two will receive a placebo, a…”In the company’s words, NCT07905053 on ClinicalTrials.gov
Coming up1
- May 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | May 2027 | A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of CBT-248 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026